Background: FUL represents a ET option for pts whose endocrine sensitive locally or advanced breast cancer (LABC) has progressed after an antiestrogen. The 500 mg monthly represents the actual standard dose showing a disease control rate of 45%-72% and a progression free survival (PFS) ranging from 6.5 to 23 months (mo) depending on treatment line. To evaluate the efficacy of FUL in unselected LABC pts we performed an observational prospective trial. Methods: Eligible pts were women with LABC suitable ET who received previous treatment with either an antiestrogen or an aromatase inhibitor (AI) as a first-line therapy, or relapsing while on or within 1 year from completion of adjuvant ET. Primary end point was the clinical benefit rate (CBR), defined as complete response (CR)...
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis
Clara Natoli;Laura Iezzi;
2016-01-01
Abstract
Background: FUL represents a ET option for pts whose endocrine sensitive locally or advanced breast cancer (LABC) has progressed after an antiestrogen. The 500 mg monthly represents the actual standard dose showing a disease control rate of 45%-72% and a progression free survival (PFS) ranging from 6.5 to 23 months (mo) depending on treatment line. To evaluate the efficacy of FUL in unselected LABC pts we performed an observational prospective trial. Methods: Eligible pts were women with LABC suitable ET who received previous treatment with either an antiestrogen or an aromatase inhibitor (AI) as a first-line therapy, or relapsing while on or within 1 year from completion of adjuvant ET. Primary end point was the clinical benefit rate (CBR), defined as complete response (CR)...I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
